Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw, +14

New England Journal of Medicine

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely, +14

The Lancet Oncology

Phase 1/2Neuro-oncologyDose-finding PortionBrain MetastasesMedicine +7

Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, +15

Journal of Clinical Oncology

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, +14

The Lancet Respiratory Medicine

MedicineRandomised Phase 3ImmunologyPathologyAlectinib Versus Crizotinib +7

Correlation of right ventricular ejection fraction and tricuspid annular plane systolic excursion in tetralogy of Fallot by magnetic resonance imaging

Peter N. Morcos, G. Wesley Vick, David J. Sahn, +3

International journal of cardiac imaging

Heart FailureRadiologyCardiac MechanicBlood Flow MeasurementMedicine +5

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer

James Chih‐Hsin Yang, Sai‐Hong Ignatius Ou, Luigi De Petris, +17

Journal of Thoracic Oncology

Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib

Neil Parrott, Li Yu, Ryusuke Takano, +2

The AAPS Journal

NutritionPharmacokinetic ModelingGastric Ph ChangesPhysiologically-based Pharmacokinetic ModelingMedicine +8

Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects

Peter N. Morcos, Li Yu, Katrijn Bogman, +11

Xenobiotica

1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

Edward Gane, S. Roberts, Catherine Stedman, +14

Journal of Hepatology

Antiviral AgentsViral Polymerase StructureMedicineAntiviral Drug DevelopmentAntiviral Therapy +6

Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects

Peter N. Morcos, Elena Guerini, Neil Parrott, +7

Clinical Pharmacology in Drug Development